Abstract:Demyelination is typically followed by a remyelination process through mature oligodendrocytes (OLs) differentiated from precursor cells (OPCs) recruited into the lesioned areas, however, this event usually results in uncompleted myelination. Potentiation of the remyelination process is an important target for designing effective therapeutic strategies against white matter loss. Here, it was evaluated the remyelinating effect of different β-carbolines that present differential allosteric modulation on the GABA A receptor expressed in OLs. For this, we used a focalized demyelination model in the inferior cerebellar peduncle ( i.c.p. ) of rats (DRICP model), in which, demyelination by ethidium bromide (0.05%) stereotaxic injection was confirmed histologically by staining with Black-Gold II (BGII) and toluidine blue. In addition, a longitudinal analysis with diffusion-weighted magnetic resonance imaging (dMRI) was made by computing fractional anisotropy (FA), apparent diffusion coefficient (ADC) and diffusivity parameters to infer i.c.p. microstructural changes. First, dMRI analysis revealed FA decreases together with ADC and radial diffusivity (RD) increases after demyelination, which correlates with histological BGII observations. Then, we evaluated the effect produced by three allosteric GABA A receptor modulators, the N-butyl-β-carboline-3-carboxylate (β-CCB), ethyl 9H-pyrido [3,4-b]indole-3-carboxylate (β-CCE), and 4-ethyl-6,7-dimethoxy-9H-pyrido [3,4-b]indole-3-carboxylic acid methyl ester (DMCM). The results indicated that daily systemic β-CCB (1 mg/Kg) or β-CCE (1 mg/Kg) administration for 2 weeks, but not DMCM (0.35 mg/Kg), in lesioned animals increased FA and decreased ADC or RD, suggesting myelination improvement. This was supported by BGII staining analysis that showed a recovery of myelin content. Also, it was quantified by immunohistochemistry both NG2 + and CC1 + cellular population in the different experimental sceneries. Data indicated that either β-CCB or β-CCE, but not DMCM, produced an increase in the population of CC1 + cells in the lesioned area. Finally, it was also calculated the g -ratio of myelinated axons and observed a similar value in those lesioned animals treated with β-CCB or β-CCE compared to controls. Thus, using the DRICP model, it was observed that either β-CCB or β-CCE, positive modulators of the GABA A receptor in OLs, had a potent promyelinating effect.

Metformin promotes CNS remyelination and improves social interaction following focal demyelination through CBP Ser436 phosphorylation

The AMPK activator metformin improves recovery from demyelination by shifting oligodendrocyte bioenergetics and accelerating OPC differentiation

Metformin promotes Schwann cell remyelination, preserves neural tissue and improves functional recovery after spinal cord injury

Metformin promotes microglial cells to facilitate myelin debris clearance and accelerate nerve repairment after spinal cord injury

Clemastine and metformin extend the window of NMDA receptor surface expression in ageing oligodendrocyte precursor cells

β-carbolines that enhance GABAA receptor response expressed in oligodendrocytes promote remyelination in an in vivo rat model of focal demyelination

Retraction Note To: Metformin Attenuates Cognitive Impairments in Hypoxia–Ischemia Neonatal Rats Via Improving Remyelination

Metformin pretreatment rescues olfactory memory associated with subependymal zone neurogenesis in a juvenile model of cranial irradiation

Small compounds mimicking the adhesion molecule L1 improve recovery in a zebrafish demyelination model

Metformin enhances neural precursor cells migration and functional recovery after ischemic stroke in mice

Metformin enhances endogenous neural stem cells proliferation, neuronal differentiation, and inhibits ferroptosis through activating AMPK pathway after spinal cord injury

Metformin Promotes Axon Regeneration after Spinal Cord Injury through Inhibiting Oxidative Stress and Stabilizing Microtubule

NEP1-40 Alleviates Behavioral Phenotypes and Promote Oligodendrocyte Progenitor Cell Differentiation in the Hippocampus of Cuprizone-Induced Demyelination Mouse Model.

Combination Therapy With Fingolimod and Neural Stem Cells Promotes Functional Myelination in vivo Through a Non-immunomodulatory Mechanism

169. Combining Metformin and Clemastine for Enhanced Remyelination in Multiple Sclerosis

Fractalkine enhances oligodendrocyte regeneration and remyelination in a demyelination mouse model

Monitoring recovery after CNS demyelination, a novel tool to de-risk pro-remyelinating strategies

Remyelination in Neuromyelitis Optica Spectrum Disorder is Promoted by Edaravone Through Mtorc1 Signaling Activation.

Scaffold-Mediated Sustained, Non-viral Delivery of miR-219/miR-338 Promotes CNS Remyelination

Pharmacological treatment promoting remyelination enhances motor function after internal capsule demyelination in mice

N-butyl-β-carboline-3-carboxylate (β-CCB) systemic administration promotes remyelination in the cuprizone demyelinating model in mice